
In 2024, gene therapy is gaining traction, driven by breakthroughs like CRISPR technology and high-cost therapies. Growing regulatory approvals and innovative solutions for rare diseases position gene therapy as a promising investment opportunity in the pharmaceutical landscape.
Amid this favorable backdrop, investors could consider keeping an eye on strong pharma stocks: Vertex Pharmaceuticals Incorporated (VRTX), Wave Life Sciences Ltd. (WVE), and Poseida Therapeutics, Inc. (PSTX).